Pharmacological Evaluation of Safoof-e-Pathar Phori- A Polyherbal Unani Formulation for Urolithiasis

Wasim Ahmad1,2*, Mohammad Ahmed Khan3, Kamran Ashraf4, Ayaz Ahmad1, Mohammad Daud Ali1, Mohd Nazam Ansari5, YT Kamal6, Shadma Wahab6, SM Arif Zaidi7, Mohd. Mujeeb2 and Sayeed Ahmad2

1Department of Pharmacy, Mohammed Al-Mana College for Medical Sciences, Dammam-34222, Saudi Arabia, 2Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, India, 3Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, India, 4Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), Cawangan Selangor, Kampus Puncak Alam, Selangor Darul Ehsan, Malaysia, 5Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkhafji, Saudi Arabia, 6Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia, 7Department of Surgery, School of Unani Medical Education and Research, Jamia Hamdard, India

Safoof-e-Pathar phori (SPP) is an Unani poly-herbomineral formulation, which has for a long time been used as a medicine due to its antiurolithiatic activity, as per the Unani Pharmacopoeia. This powder formulation is prepared using six different plant/mineral constituents. In this study, we explored the antiurolithiatic and antioxidative potentials of SPP (at 700 and 1,000 mg/kg) in albino Wistar rats with urolithiasis induced by 0.75% ethylene glycol (EG) and 1% ammonium chloride (AC). Long-term oral toxicity studies were performed according to the Organization for Economic Co-operation and Development (OECD) guidelines for 90 days at an oral dose of 700 mg/kg of SPP. The EG urolithiatic toxicant group had significantly higher levels of urinary calcium, serum creatinine, blood urea, and tissue lipid peroxidation and significantly (p < 0.001 vs control) lower levels of urinary sodium and potassium than the normal control group. Histopathological examination revealed the presence of refractile crystals in the tubular epithelial cell and damage to proximal tubular epithelium in the toxicant group but not in the SPP treatment groups. Treatment of SPP at 700 and 1,000 mg/kg significantly (p < 0.001 vs toxicant) lowered urinary calcium, serum creatinine, blood urea, and lipid peroxidation in urolithic rats, 21 days after induction of urolithiasis compared to the toxicant group. A long-term oral toxicity study revealed the normal growth of animals without any significant change in hematological, hepatic, and renal parameters; there was no evidence of abnormal histology of the heart, kidney, liver, spleen, or stomach tissues. These results suggest the usefulness of SPP as an antiurolithiatic and an antioxidant agent, and long-term daily oral consumption of SPP was found to be safe in albino Wistar rats for up to 3 months. Thus, SPP may be safe for clinical use as an antiurolithiatic formulation.

Keywords: Urolithiasis, antioxidant, ethylene glycol, ammonium chloride, safoof-e-pathar phori, long term oral toxicity
INTRODUCTION

Urolithiasis is the formation of a stone in the kidney, and it is the most common medical problem in humans. Kidney stones have been reported even before 4000 BC in Egyptian mummies and in remains of old North American Indians dating back to 1,500–1000 BC (Patankar et al., 2008). Kidney stones affect up to 5% of the population, with a lifetime risk of passing a kidney stone in approximately 8–10% of the population (Asplin et al., 1996). Presumably, nearly 12% of the global population is affected by kidney stones, with a higher recurrence rate in males than in females (70–80% vs 47–60%) (Soundararajan et al., 2006).

Urolithiasis is a complex process because stones can originate in any part of the urinary tract and kidney, leading to a deficiency of various vitamins and hormones in the body. The frequency of stones in men is twice as high compared to women, and the prevalence is highest among men aged between 30 and 35 years and among women aged between 35 and 55 years (Sutherland et al., 1985; Srinivas et al., 2012). Kidney stone formation or urolithiasis is a complex process that arises due to differences among promoters and inhibitors in the kidneys (Sathish et al., 2010). Factors affecting stone formation are urinary output (hence, the concentration), concentration of a particular component, urinary pH, and infection or injury within the urinary tract (Michell et al., 1989).

Stones are made up of various components. The first step in the formation of any stone is the supersaturation of urine (Chandhoke, 2002). Calcium oxalate (CaOx) is the principal constituent of most stones, accounting for more than 80% of stones (Moe, 2006), and the remaining 20% of the stone comprises struvite, cystine, uric acid, and other stones (Park and Pearle, 2007). As mentioned, calcium stone formation is caused by supersaturation of the urine with calcium salts forming a stone. Metabolic irregularities such as hypercalciuria, hypocitraturia, hyperoxaluria, hyperuricosuria, and gouty diathesis can change the composition or saturation of urine, increasing the risk of stone formation. Urolithiasis requires preventive and curative therapies because of its high recurrence rate.

Presently, no suitable drugs are available in modern medicine for the prevention and management of kidney stones. Thiazide diuretics and alkali citrate, the most effective hypocalciuric agents, are used to prevent kidney stone formation; however, no allopathic medicine is available for the dissolution or expulsion of the kidney stone (Ikshit et al., 2017). Treatment and management of renal stones relies on surgical techniques, such as extracorporeal shock wave lithotripsy, percutaneous lithotripsy, and transureteral lithotripsy (Mandavia et al., 2013; Mina et al., 2018). These surgeries are complex and expensive and do not affect the recurrence of stones. However, they cause adverse effects including tubular necrosis (Ikshit et al., 2017), hypertension, hemorrhage, and subsequent fibrosis of the kidney (Hardik et al., 2016), which cause cell injury and reappearance of the renal stone (Kaur et al., 2009).

Medicine obtained from herbal sources is a substitute and last resort drug for the prevention and treatment of kidney stones. Several medicinal plants have been used because of their curative and preventive properties against urinary calculi for example, *Didymocarpus pedicellatus* R. Br (leaf) (Ahmad et al., 2014; Khaling et al., 2014), *Tribulus terrestris* L (fruit and leaves), *Solanum virginianum* L (fruit) (Kumar and Pandey, 2014), and Gokshuradi churan (an ayurvedic formulation) are commonly and frequently used in traditional medicine in India (Srinivas et al., 2013).

Traditional medicine provides several alternatives for modern invasive operational treatments in allopathy, for instance, the use of Safoof-e-Pathar phori (SPP) in the treatment of urolithiasis (Anonymous, 1986; Ahmad et al., 2016). SPP, for the treatment of urolithiasis, has been used for a long time in the Unani system of medicine and has been found to be a clinically sound medicine.

In the Unani system of medicine, powdered drugs are termed ‘Safoof’. Safoof is an important class of Unani medicinal preparations, which are obtained by powdering and mixing herbs, metals, minerals, and animal products (Dubey et al., 2008). SPP is an Unani poly-herbomineral formulation, and has been used as a medicine for a long time because of its antiurolithic activity, as per Unani Pharmacopoeia (Anonymous, 1986). This powder formulation is prepared using plant and mineral constituents such as *Didymocarpus pedicellatus* R. Br (Grneriaeaceae) (Anonymous, 2006; Ahmad et al., 2014; Ahmad et al., 2017), *Macrotlyoma biflorum* var. *biflorum* (Leguminosae) (Anonymous, 2007a), *Rheum webbianum* Royle (Polygonaceae) (Anonymous, 2007b; Ahmad W. et al., 2014), *Rheum raphanistrum subsp. sativus* (L.) Domin (Brassicaceae), *Hordeum vulgare* Linn (Poaceae), and potassium nitrate (Ahmad et al., 2013; Ahmad W. et al., 2014; Zaidi and Ahmed, 2016).

Ahmad et al. (2016) reported extensive quality control analysis of SPP for the first time, which comprised phytochemical and physicochemical analyses, high-performance thin-layer chromatography (HPTLC), high-performance liquid chromatography (HPLC), and gas-chromatography coupled to mass spectrometry (GC-MS) fingerprinting profiles, to check the authenticity and to determine the adulterants in this traditional formulation. Quantitative estimation of marker compounds such as emodin (C_{15}H_{10}O_{5}; 98% purity), chrysophanic acid (C_{15}H_{10}O_{4}; 98% purity), and alpha-humulene (96% purity) in SPP has been performed using various analytical techniques such as HPTLC, HPLC photodiode array detector, ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry, and GC-MS (Ahmad W. et al., 2014; Ahmad et al., 2015; Ahmad et al., 2016; Ahmad et al., 2019). Additionally, a quality control analysis of individual constituents of SPP (*Didymocarpus pedicellatus* R. Br, *Macrotlyoma biflorum* var. *biflorum*, and *Rheum webbianum* Royle) has been reported (Ahmad et al., 2010; Ahmad et al., 2013; Ahmad W. et al., 2014; Ahmad et al., 2017). Ahmad et al. (2020) reported a comprehensive quality assessment method consisting of HPTLC, HPLC, and GC-MS comparative fingerprinting profiles for SPP and its constituents, using extracts in petroleum ether, chloroform, methanol, and hexane to provide further chemical information. This method can be used for the identification of crude drugs present in other herbal formulations. HPTLC fingerprint profiles of petroleum ether, chloroform, and...
methanol extracts displayed different bands at different wavelengths for SPP and its constituents. Various solvent systems, chemical compositions, and chromatograms are reported by Ahmad et al. (2020). The HPLC fingerprint profile data showed the presence of 23, 14, 10, and 13 compounds was detected in methanolic extracts of SPP, Didymocarpus pedicellatus R. Br., Macrotyloma biflorum var. biflorum, and Rheum webbianum Royle respectively, whereas the GC-MS fingerprint profile demonstrated the presence of 22, 51, 28, and 16 metabolites in hexane extracts of SPP, Didymocarpus pedicellatus R. Br., Macrotyloma biflorum var. biflorum, and Rheum webbianum Royle respectively, which were identified by reviewing NIST and Wiley libraries on the basis of m/z (Ahmad et al., 2020). The formulation and composition used in this study are similar to those described by Ahmad et al. (2020).

To the best of our knowledge, no published scientific evidence is available to prove the effectiveness of SPP in urolithiasis. Hence, this study aimed to investigate phytochemical-based lithotriptic activity of SPP. In addition to investigating the therapeutic effects, obtaining comprehensive toxicological information on SPP is essential to ensure safety upon use, mainly for long-term use. Therefore, this study was conducted to evaluate the effect of SPP [same formulation as used by Ahmad et al. (2014), Ahmad W. et al. (2014), Ahmed et al. (2015), Ahmed et al. (2019), Ahmed et al. (2020).]

**Method of Safoof-e-Pathar Phori Preparation**

SPP was prepared as per the process described in Qarabadeen Majeedi. For the 100 g unit formula for SPP preparation, finely powdered plant drugs: Didymocarpus pedicellatus R. Br.50 g, Macrotyloma biflorum var. biflorum12.5 g, Rheum webbianum Royle12.5 g, salts: Hordeum vulgare Linn. 12.5g, Raphanus raphanistrum subsp. sativus (L.), Domi 6.25 g, and potassium nitrate 6.25 g were mixed properly and passed through mesh # 60 to obtain a uniform powder (Table 1). This formulation was prepared in the bioactive natural product laboratory, Jamia Hamdard, New Delhi, and a voucher specimen was submitted to the lab BNPL/SPP/02/2010. The same formulation and composition were used by Ahmad et al. (2014), Ahmad W. et al. (2014), Ahmed et al. (2015), Ahmed et al. (2019), Ahmed et al. (2020).

**Chemicals and Apparatus**

Biochemical kits for the estimation of calcium, sodium, and potassium were purchased from Span Diagnostics Ltd, Surat, India. All the chemicals were purchased from Sigma Chemicals Co., St Louis, United States, and Hi-media, Mumbai. Apparatus including metabolic cages (INCO, Ambala, India), refrigerated research centrifuge (Remi centrifuge instrument, Mumbai), and UV-spectrometer (model UV 1800; Shimadzu, Japan) were used in the study.

**Experimental Animals**

Male albino Wistar rats (body weight range 180–220 g) were used for the pharmacological (antiurolithic and antioxidant activities) studies, and healthy young adult male and female albino Wistar rats (weighing 125–160 g) were used for the long-term oral toxicity studies. Females were nulliparous and non-pregnant. Animals were procured from the central animal house facility of Jamia Hamdard. The study protocol was approved by the Institutional Animal Ethics Committee (Registration Number 173/CPCSEA and Approval Number 691) following guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India.
All animals were fed a standard laboratory diet and maintained under standard laboratory conditions (temperature, 22–24°C; relative humidity, 60–70%), standard light and dark cycle, and water *ad libitum*. All the healthy albino Wistar rats were allowed to acclimatize for 1 week prior to the experiment.

**Ethylene Glycol- and Ammonium chloride-Induced Urolithiasis**

Animals were divided into the following five groups (six animals in each group): control, toxicant, Safoof-e-Pathar phori lower dose (SPPL) treatment group, Safoof-e-Pathar phori higher dose (SPPH) treatment group, and neeri syrup standard group (Table 1). To induce CaOx crystal formation, animals were exposed to 0.75% EG with 1.0% AC in their drinking water for 21 days (Bashir and Gilani, 2009). The experimental groups are summarized as follows:

- **Group I**: Normal rats; received vehicle along with simple drinking water for 21 days.
- **Group II**: Toxicant; received 0.75% EG with 1.0% AC in drinking water for 5 days and 0.75% EG for the next 16 days.
- **Group III**: Standard; received 0.75% EG with 1.0% AC in drinking water for 5 days and 0.75% EG for the next 16 days along with the standard drug neeri 2.65 ml/kg/day for all 21 days.
- **Group IV**: SPPL; received 0.75% EG with 1.0% AC in drinking water for 5 days and 0.75% EG for the next 16 days along with SPP at 700 mg/kg/day for all 21 days.
- **Group 5**: SPPH; received 0.75% EG with 1.0% AC in drinking water for 5 days and 0.75% EG for the next 16 days along with SPP at 1,000 mg/kg/day for all 21 days.

For the antiurolithic study, fresh suspensions of SPP (700 and 1,000 mg/kg; using 0.25% CMC) were administered once daily by oral gavage to the corresponding group of animals for 21 days.
Low and high-power photomicrograph of SPP treated rats showed the normal histological appearance without any significant change in heart, kidney, liver, spleen and stomach compare to normal control rats. Histopathological examination of heart tissue showed normal appearance of cardiac muscle fibers and no evidence of necrosis or myocardial damage is seen. Cardiac muscle fibers with striated cytoplasm and central oval nuclei. A coronary vessel (Art.) cut in cross section is also seen. Histopathological examination of kidney tissues showed normal histopathological appearance of renal parenchyma, glomerular tubule in all treatment groups including control. The histopathological examination of stomach tissues showed normal histological appearance of different layers of stomach walls and mucosa of the stomach showing gastric glands in photomicrographs of all treatment groups including control. Histopathological examination of liver tissues showed normal histological appearance of portal triad (PT), central vein (CV) (100×), bile duct (BD) and portal vein (PV) (400×) in all treatment group including control. The histopathological examination of spleen tissues showed normal histological appearance of white pulp (WP), red pulp (RP) (100×), areas in the splenic parenchyma. Splenic arteriole (SA) and lymphocytes in photomicrographs of all treatment groups including control.

| S. No | Ingredients common name | Ingredients botanical name | Family (part used) | Category | Unit formula per 100 g |
|-------|-------------------------|---------------------------|-------------------|----------|-----------------------|
| 1     | Pathar phori            | Didymocarpous pedicellatus R.Br | Gesneriaceae (leaves) | Active ingredient | 50 g |
| 2     | Jawahar desi            | Hordeum vulgare L | Poaceae (whole plant) | Active ingredient | 12.5 g |
| 3     | Rewand chi              | Rheum webbianum Royle | Polygonaceae (Rhizone) | Active ingredient | 12.5 g |
| 4     | Namak turb              | Raphanus raphanistrum subsp. sativus (L.) domin | Brassicaceae (Whole plant) | Active ingredient | 6.25 g |
| 5     | Kulthi                   | Macrotyloma biflorum var. biforum | Leguminosae (Seed) | Active ingredient | 12.5 g |
| 6     | Shora qalmi             | Potassium Nitrate | Total | Active ingredient | 6.25 g |

Total 100
**Long-Term Oral Toxicity Study**

Young adult male and female albino Wistar rats were divided into the following four groups (five rats in each group):

- **Group I**: Normal control (NC); consisting of males receiving vehicle 0.4 ml/animal daily for 90 days.
- **Group II**: NC; consisting of females receiving vehicle 0.4 ml/animal daily for 90 days.
- **Group III**: SPP (700 mg/kg/day for 90 days); consisting of males.
- **Group IV**: SPP (700 mg/kg/day for 90 days); consisting of females.

For the long-term oral toxicity study, a freshly prepared suspension of SPP (700 mg/kg) was administered daily in the rats for 90 days. The animals were dosed at approximately the same time each day. All animals were observed daily for body weight and mortality throughout the study. Histopathological and biochemical changes in the animals were analyzed at the end of the study period following sacrificing of the animals.

**Collection and Analysis of Urine**

On the 21st day, animals were kept in a urine collection cage, and urine from the first 3 h of the morning was collected for investigation of crystalluria. All the animals were kept individually in the metabolic cages, and the urine sample at 24 h was collected. The urine samples were acidified by adding a few drops of concentrated HCl and stored at 4°C until further use. Urine was also analyzed for calcium, sodium, and potassium as per the manufacturer’s protocol (Span Diagnostics Ltd, Surat, India) (Ikshit et al., 2017).

**Hematological and Serum Biochemical Analysis**

Blood samples were collected 24 h after the last dose of treatment by puncturing the retro-orbital sinus under a mild anesthetic condition, and the animals were sacrificed by cervical decapitation. In the pharmacological study, hematological parameters such as hemoglobin (Hb), total red blood cells (RBCs), and white blood cells (WBCs) were analyzed in the whole blood. The serum was separated by centrifugation at 1,500 rpm for 15 min in refrigerated research centrifuge and used for the estimation of serum creatinine and blood urea nitrogen (BUN) using commercially available kits (Span Diagnostics Ltd, Surat, India) and the Star-21 plus semi-auto analyzer. In long-term oral toxicity studies, hematological parameters such as Hb, erythrocyte count, total leukocytes and biochemical parameters in the blood serum including serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, urea, albumin, bilirubin, total protein, creatinine, uric acid, sodium, and potassium were analyzed using commercially available kits (Span Diagnostics Ltd, Surat, India) as per the manufacturer’s protocol.

**RESULTS**

**Antiureolithiatic Effect of Safoof-e-Pathar Phori on Ethylene Glycol Induced Urolithiasis**

The concentrations of urinary calcium, potassium, and sodium in groups I–V are given in Table 2. In this study, 0.75% EG (v/v) with 1% AC induced urolithiasis in male rats and resulted in hypercalciuria and hyperoxaluria. The level of urinary calcium was significantly elevated compared with the Normal control (NC) (Table 2). However, rats treated with SPPL (700 mg/kg; Group IV) and SPPH (1,000 mg/kg; Group V) demonstrated significantly lower calcium levels and increased potassium and sodium excretion in urine than those in NC (p < 0.01). A decrease in calcium and an increase in potassium and sodium in SPPL and SPPH treated rats were similar to those in Neeri-treated rats (Group III).

Urolithiasis induced by EG and AC caused impairment of renal functions in untreated rats as marked by the increased levels of serum creatinine, uric acid, and urea. Renal function was evaluated by determining the serum creatinine and BUN in EG- and AC-induced urolithiasis and treated rats (Table 2). Levels of serum creatinine and BUN were significantly increased in the toxicant group when compared with the NC, indicating impairment of renal functions. However, SPPL (700 mg/kg) and SPPH (1,000 mg/kg) significantly (p < 0.001) decreased the levels of serum creatinine and BUN excreted by kidneys compared with the toxicant group. Moreover, treatment with SPPL (700 mg/kg) and SPPH (1,000 mg/kg) significantly lowered the elevated serum creatinine level, SPPH showed dose-dependent activity due to maximum decrease in serum creatinine and BUN levels. These results suggested that SPP treatment ameliorates the renal functions compared with urolithic control rats. The results of SPP were found to be similar to those of the standard drug neeri.

**Histopathological Study of the Kidney, Heart, Liver, Stomach, and Spleen**

For investigating the antiureolithiatic activity, the sacrificed animals were dissected after blood sample collection, and only the kidneys were removed and immediately washed with ice-cold saline. After washing with saline, kidneys were preserved for biochemical estimation and fixed in 10% formalin for histopathological studies. For the long-term oral toxicity study, the kidney, heart, liver, stomach, and spleen of animals were dissected. Isolated organs were fixed in 10% neutral buffered formalin, processed in a series of graded alcohol and xylene, and finally embedded in paraffin wax. Histological sections (approximately 5 μm thickness) were prepared by microtomy and stained with hematoxylin and eosin dye for histological examination. Histological slides were examined under a light microscope at low (10×) and high (40×) magnifications. Statistical Analysis

Results are expressed as mean ± standard deviation. A two-way analysis of variance followed by a Tukey's test was used for statistical analysis. A p value of <0.05 was considered statistically significant.
The antioxidant parameters were assessed by measuring the malondialdehyde (measured as TBARS) and glutathione (GSH) level. Treatment with EG and AC significantly increased (p < 0.001) the TBARS level and decreased the GSH level in urolithiasis-induced rats compared with NC (Table 2). Treatment with SPPL (700 mg/kg) and SPPH (1,000 mg/kg) decreased the TBARS level significantly (Figure 1) and improved the GSH concentration (Figure 2) compared with the toxicant group.

The crystalluria study revealed the absence of crystals (oxalate crystals) in the rat group treated with standard neeri syrup (2.65 ml/kg), SPPL (700 mg/kg), and SPPH (1,000 mg/kg), which supported the preventive effect of low and high doses of SPP on the induction of urolithiasis. Hematological analysis of various groups of rats showed normal RBC, WBC, and Hb levels and absence of hemolysis in all the groups (Table 2).

Figure 3 shows the histopathological examination of the rat kidneys. The histopathological section of the kidneys of rats in the toxicant group exhibited no abnormalities; glomerulus and proximal tubules were normal (Figure 3A). The kidneys of rats in the toxicant group exhibited damaged proximal tubules, with deposits of refractile crystals and loss of tubular epithelium. The distal tubules were not affected, and glomeruluses did not show any damage. It exhibited the characteristic signs of stone development on continuous ingestion of 0.75% EG with 1.0% AC (Figure 3B). The kidneys of rats in the urolithic group treated with SPPL (700 mg/kg/day) exhibited a single damaged proximal tubule with loss of tubular epithelium with several undamaged tubules around it (Figure 3C), whereas those treated with SPPH 1000 mg/kg/day exhibited a normal glomerulus and tubules. No evidence of tubular damage was observed in this sample (Figure 3D). However, the kidneys of rats in the neeri standard group exhibited a few dilated tubules along with numerous undamaged tubules (Figure 3E).

**DISCUSSION**

The most commonly used medical therapies in the management of urolithiasis include calcium channel blockers, steroids, and α1 adrenergic blockers (Shekar and Patki, 2011), which exhibit some adverse effects. Some herbal remedies have been used in the management of urinary calculi; however, their efficacy has not been scientifically proven. With the understanding of various pathophysiological functions underlying renal stones and the mechanism of herbal remedies that can play a role in preventing the formation and management of urinary calculi, phytotherapy might be a better alternative in the preventive and curative management of urinary calculi. Oral citrate is the most commonly used medicinal agent in the prevention of urinary
TABLE 3 | Mortality record of animals in control and treatment group.

| Days  | Control male | Control female | SPP 700 mg/kg male | SPP 700 mg/kg female |
|-------|--------------|----------------|-------------------|---------------------|
| Week 1 | -            | -              | -                 | -                   |
| Week 2 | -            | -              | -                 | -                   |
| Week 3 | -            | -              | -                 | -                   |
| Week 4 | -            | -              | -                 | -                   |
| Week 5 | -            | -              | -                 | -                   |
| Week 6 | -            | -              | -                 | -                   |
| Week 7 | -            | -              | -                 | -                   |
| Week 8 | -            | -              | -                 | -                   |
| Week 9 | -            | -              | -                 | -                   |
| Week 10 | -           | -              | -                 | -                   |
| Week 11 | -           | -              | -                 | -                   |
| Week 12 | -           | -              | -                 | -                   |
| Week 13 | -           | -              | -                 | -                   |
| Mortality | 0/5 | 0/5 | 0/5 | 0/5 |

SPP-Safoof-e-Pathar phori.

TABLE 4 | Body weight records of animals in male and female rats orally treated with SPP 700 mg/kg and control group.

| Dose     | Male (g) | SPP 700 | Female (g) | SPP 700 |
|----------|----------|---------|------------|---------|
| 0 Week (18/07/2010) | 148 ± 13.26 | 142 ± 11.66 | 133.43 ± 38.36 | 128.22 ± 36.55 |
| Week 1 (25/07/2010) | 149 ± 14.96 | 147 ± 11.66 | 136.16 ± 38.60 | 131.97 ± 37.66 |
| Week 2 (01/08/2010) | 158 ± 14.35 | 157 ± 11.66 | 142.69 ± 40.84 | 141.13 ± 40.33 |
| Week 3 (08/08/2010) | 163 ± 14.35 | 164 ± 11.13 | 147.69 ± 42.45 | 147.92 ± 42.20 |
| Week 4 (15/08/2010) | 169 ± 13.56 | 175 ± 8.94  | 152.29 ± 43.86 | 157.41 ± 45.49 |
| Week 5 (22/08/2010) | 173 ± 14.35 | 183 ± 6.63  | 156.02 ± 44.83 | 163.05 ± 47.41 |
| Week 6 (29/08/2010) | 180 ± 12.64 | 189 ± 6.63  | 161.88 ± 47.14 | 169.63 ± 49.74 |
| Week 7 (05/09/2010) | 184 ± 12    | 195 ± 7.07  | 166.33 ± 48.60 | 175.58 ± 51.33 |
| Week 8 (12/09/2010) | 189 ± 10.19 | 201 ± 8      | 171.59 ± 50.05 | 182.41 ± 53.03 |
| Week 9 (19/09/2010) | 196 ± 11.57 | 209 ± 8      | 177.71 ± 51.42 | 189.75 ± 55.29 |
| Week 10 (26/09/2010) | 202 ± 12.08 | 214 ± 3.74  | 183.67 ± 53.28 | 193.97 ± 57.71 |
| Week 11 (3/10/2010) | 208 ± 12.88 | 221 ± 3.74  | 190.07 ± 54.88 | 199.97 ± 59.50 |
| Week 12 (10/10/2010) | 214 ± 13.92 | 228 ± 4      | 196.49 ± 56.62 | 206 ± 61.18 |
| Week 13 (17/10/2010) | 225 ± 12.24 | 236 ± 3.74  | 206.85 ± 59.57 | 214.14 ± 63.64 |

calculi (Gurocak et al., 2006). Because of the adverse effects of these agents, alternative management modalities comprising herbal remedies have been significant agents in the treatment (Gurocak et al., 2006). The use of medicinal plants to treat diseases is as old as civilization itself. Plants provide crude drugs, which are used without any modification, and numerous chemical constituents can be used for the synthesis of new drugs with better pharmacological effects (Potterat and Hostettman, 1995; Zaidi and Ahmad, 2016). Additionally, the World Health Organization (WHO) has highlighted the development and application of herbal and traditional medicines concerning their beneficial effects, such as cost-effectiveness and the avoidance of side effects of synthetic medicines. The WHO has estimated that approximately 80% of the population living in the developing countries rely on traditional medicines for their healthcare needs (WHO, 2002).

The present study was performed to evaluate the antiurolithiatic effects of SPP on EG-induced urolithiasis in male Wistar rats used by several investigators. (Bashir and Gilani, 2009; Pareta et al., 2011; Aggarwal et al., 2012; Lin et al., 2012; Nanu et al., 2012; Saiedi et al., 2012; Khan et al., 2016).

EG is a metabolic precursor of oxalate. EG is oxidized to glycolic acid and further to oxalic acid. Administration of EG causes hypercalciuria, leading to urolithiasis. Administration of EG causes hypercalciuria and hyperoxaluria to induce urolithiasis (Verma et al., 2009). AC ingestion, which induces metabolic acidosis, has been used in conjunction with EG to promote the deposition of CaOx crystals in the rat kidneys. Various doses of AC in combination with EG resulted in CaOx depositions in the rat kidneys within 7 days (Khan et al., 2016). After 21 days, crystalluria analysis of rats in the EG-induced urolithiasis group revealed that untreated rats exhibited bigger crystals than treated rats (Bashir and Gilani, 2009). Studies have consistently reported that calculi induced by hyperoxaluria causes an increase in oxalate and a decrease in calcium excretions in the toxicant group (Fan et al., 1999; Park et al., 2007); SPP treatment produced reversible effects in a dose-dependent manner.

Results of the urinary calcium level showed a significant (p < 0.001 vs control) elevation in the toxicant group, whereas sodium and potassium level significantly (p < 0.001 vs control) reduced compared
TABLE 5 | Results of hematological, liver, renal and organ weight assessment of control and SPP 700 mg/kg group.

| Test                  | Control Male | SPP 700 Male | Control Female | SPP 700 Female |
|-----------------------|--------------|--------------|----------------|---------------|
| Erythrocyte count (mill/l) | 5.81 ± 0.01  | 7.30 ± 0.06  | 5.31 ± 1.59    | 6.61 ± 1.97   |
| Hemoglobin (g/dl)      | 9.84 ± 0.16  | 13.22 ± 0.08 | 9.52 ± 2.88    | 11.70 ± 3.53  |
| Total leukocytes       | 11.84 ± 0.10 | 11.18 ± 0.06 | 10.49 ± 3.16   | 10.14 ± 3.04  |
| Bilirubin (mg/dl)      | 0.00 ± 0.02  | 0.88 ± 0.01  | 0.00 ± 0.25    | 0.79 ± 0.23   |
| SGPT (U/L)             | 30.92 ± 0.66 | 69.68 ± 0.93 | 27.69 ± 8.21   | 63.55 ± 18.89 |
| SGOT (U/L)             | 35.26 ± 0.34 | 67.4 ± 0.61  | 32.24 ± 9.63   | 60.95 ± 18.22 |
| ALP (U/L)              | 75.11 ± 0.28 | 25.34 ± 0.53 | 67.90 ± 20.42  | 14.73 ± 10.67 |
| Total Protein (g/dL)   | 0.00 ± 0.01  | 0.04 ± 0.08  | 0.57 ± 1.69    | 0.26 ± 1.26   |
| Albumin (g/dL)         | 0.12 ± 0.14  | 1.30 ± 0.02  | 0.27 ± 0.80    | 0.18 ± 0.35   |
| Blood Urea (mg/dl)     | 34.6 ± 1.01  | 49.22 ± 0.16 | 31.30 ± 9.19   | 81.90 ± 124.3 |
| Creatinin (mg%)        | 0.07 ± 0.02  | 0.44 ± 0.01  | 0.06 ± 0.19    | 0.40 ± 0.11   |
| Serum Uric acid (mg/100 ml) | 0.00 ± 0.10 | 0.04 ± 0.11  | 0.06 ± 0.19    | 0.27 ± 2.16   |
| Sodium (mg/L)          | 143.8 ± 2.31 | 140 ± 1.41   | 130.42 ± 38.70 | 127.03 ± 37.95 |
| Potassium (meq/L)      | 0.16 ± 0.13  | 0.24 ± 0.13  | 0.09 ± 1.09    | 0.48 ± 1.93   |
| Kidney                 | 0.68 ± 0.01  | 0.69 ± 0.007 | 0.61 ± 0.18    | 0.63 ± 0.18   |
| Spleen                 | 0.31 ± 0.01  | 0.31 ± 0.01  | 0.28 ± 0.08    | 0.29 ± 0.08   |
| Heart                  | 0.40 ± 0.01  | 0.61 ± 0.006 | 0.23 ± 0.11    | 0.37 ± 0.11   |
| Liver                  | 2.01 ± 0.08  | 1.94 ± 0.10  | 1.87 ± 0.54    | 1.80 ± 0.51   |
| Stomach                | 0.38 ± 0.02  | 0.37 ± 0.007 | 0.35 ± 0.10    | 0.34 ± 0.10   |

to the control group. Sodium and potassium levels significantly (p < 0.001 vs toxicant) increased, and calcium levels were decreased in the urine of the rats treated with SPP compared with the toxicant group. Comparison of the SPP and Neeri group showed an insignificant difference. This suggests an increased urinary loss of electrolytes (Hess and Kok, 1996). In urolithiasis, creatinine and BUN accumulate in blood. In this study, we observed that serum creatinine and BUN levels were significantly (p < 0.001 vs control) elevated in the serum of rats with EG- and AC-induced urolithiasis (toxicant group). It is suggested that EG and AC cause renal tubular damage and lower glomerular filtration rate. SPP-treated rats significantly (p < 0.001 vs. toxicant) reduced the BUN and serum creatinine levels compared with the control group at the dose of 700 and 1,000 mg/kg, and these results were similar to those of the standard drug Neeri.

The toxicant group showed a significantly (p < 0.001 vs control) elevated level of TBARS compared to the control group. Lipid peroxidation was measured as a Nano-gram of TBARS per mg of protein level in kidney tissue. Lipid peroxidation is another critical cause of injury that occurs during urolithiasis. Increased TBARS levels due to increased oxidative stress, decreased antioxidant enzymes and GSH levels in kidneys, and impaired kidney functions. Oxalate has been reported as the major stone forming component causing peroxidative injury to the renal epithelial cells (Kato et al., 2007). The SPP treatment protected against various injuries associated with oxidative stress. The biochemical alterations were supported by histopathological interpretations of the kidney (Muthukumar and Selvam, 1998). The urolithiasis toxicant group exhibited the presence of refractile crystals in the tubular epithelial cell and damage to the proximal tubular epithelium, whereas groups treated with SPP along with EG and AC exhibited protection, as evident from the reduction in tubular cell damage and normal kidney histology. Our results suggest that SPP has both protective and preventive effects in rats with EG- and AC-induced urolithiasis, which is consistent with previous studies (Saha and Verma, 2011). Zaidi and Ahmad (2016) reported that SPP is an effective and safe non-invasive polyherbal remedy for patients with urolithiastic, with no adverse reactions.

Medicinal plants and herbal medicines are progressively required by patients as a source of prescription drugs, in the form of active constituents, in developed and developing countries. They have been shown to possess undeniable and tangible therapeutic benefits with limited toxicity because of their long-term use as traditional medicines. The WHO claims that safety is a critical parameter of herbal medicines in the quality control of healthcare products (Tatke et al., 2012). Toxicity studies are considered to be important during new drug development, keeping in mind that herbal medicines are frequently used indiscriminately without considering their potential side effects, which can vary from mild–severe to life-threatening (World Health Organization, 1987; World Health Organization, 2000). Various herbal preparations have been shown to be beneficial in treating kidney disease; however, the toxicity and safety data for many of these herbal treatments are not available (Tatke et al., 2012).

In this study, the long-term oral toxicity of SPP was evaluated in albino Wistar rats using biochemical, hematological, and histopathological parameters. Weight gain and behavioral activity was similar to the control animals in all single-dosed males and females during the study period. There were no marked abnormal changes observed throughout the study period. Histopathology in rats at a single dose of SPP exhibited insignificant differences compared to the control group. Additionally, the functioning of major organs (heart, kidney, liver, spleen, and stomach) was found to be similar to that in the control group. Histopathological examination of the heart, kidney, liver, spleen, and stomach did not exhibit any changes. Oral SPP ingested at 700 mg/kg for up to 3 months resulted in normal growth with no changes in hematological, hepatic, or renal functioning parameters. There was no evidence of abnormal histology. Thus, long-term daily oral consumption of SPP
was found to be safe in Wistar rats, and it may be safe for clinical use as an antiurolithiatic formulation.

CONCLUSION

The results indicated that the administration of the traditional Unani poly-herbomineral formulation SPP reduced and prevented the growth of urinary stones in rats with EG- and AC-induced urolithiasis. The toxicity study indicated no serious signs and significant changes in the physical, hematological, biochemical, and histopathological parameters after 90-days administration of SPP (700 mg/kg). SPP was found to be safe for oral administration at 700 mg/kg for up to 3 months. Hence, SPP was observed to be a curative and safe poly-herbomineral formulation, useful in the prevention and management of urolithiasis. Further studies at lower dose levels and using extracts of the formulation to reduce the dose are necessary to make it more pharmacologically relevant and to elucidate the mechanism underlying the pharmacological effect of SPP.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

REFERENCES

Aggarwal, A, Singla, SK, Gandhi, M, and Tandon, C (2012). Preventive and curative effects of Achyranthes aspera Linn. extract in experimentally induced nephrolithiasis. Indian J. Exp. Biol. 50, 201–8.

Ahmad, W., Ali, A., Ali, M., Mir, S. R., Zaidi, S. M. A., and Ahmad, S. (2017). New fatty acid and aromatic monoterpenic esters from the leaves of Didymocarpus pedicellata R. Br. Indian Drugs. 54 (11), 28–32.

Ahmad, W., Khan, W., Khan, M. S., Mujeeb, M., Zaidi, S. M. A., and Ahmad, S. (2016). Quality control analysis of Safoof-e-Pathar phori: antiurolithiatic formulation. Drug Dev. Ther. 7 (1), 20–25. doi:10.4103/2394-6555.180163

Ahmad, W., Mujeeb, M., Zaidi, S. M. A., and Ahmad, S. (2013). Current strategy for research on quality identification of Rheum emodi Wall. rhizome. Int. J. Drug Dev. Res. 5, 1–10.

Ahmad, W., Mujeeb, M., and Zaidi, S. M. A. (2010). Quality control analysis of seed of Dolichos biflorus Linn. Int. J. Drug Dev. Res. 2, 669–674.

Ahmad, W., Parveen, R., Mujeeb, M., and Zaidi, S. M. A. (2020). Comparative fingerprint profiling of Unani polyherbomineral (Safoof-e-Pathar phori) formulation by HPTLC, HPLC, and GC-MS. J. AOAC Int. 103, 659–668. doi:10.5740/jaoacint.19-0286

Ahmad, W., T. Tamboli, E., Ali, A., Amir, M., Zaidi, S. M. A., and Ahmad, S. (2019). Didymocarpus pedicellatus R. Br.: qualitative and quantitative GCMS approach for quality control in traditional poly-herbal formulation with in vitro antioxidant and antimicrobial activity. Orient. J. Chem. 35, 648–657. doi:10.13005/ojc/350229

Ahmad, W., Zaidi, S. M. A., and Ahmad, S. (2014). Quality control analysis of Didymocarpus pedicellata R. Br. Indian J. Traditional Knowledge. 13, 175–180.

Ahmad, W., Zaidi, S. M. A., Mujeeb, M., Ansari, S. H., and Ahmad, S. (2014). HPLC and HPTLC methods by design for quantitative characterization and in vitro anti-oxidant activity of polyherbal formulation containing Rheum emodi. Journal of Chromatographic Science 52, 911–918. doi:10.1093/chromsci/bmt123

Ahmad, W., Zaidi, S. M. A., and Ahmad, S. (2015). Validated UPLC-Q-TOF-MS method for quantitative determination of emodin in rhizome of Rheum emodi Wall. ex Meiss. and its traditional polyherbal formulation using three different extraction techniques. Ann. Phytomedicine 4, 68–73.

Anonymous (2006). The wealth of India second supplement series raw material. 58.

Anonymous (2007a). The Unani Pharmacopoeia of India. 54–59.

Anonymous (2007b). The Unani Pharmacopoeia of India. 91–92.

Anonymous (1986). Qarabadeen majeddi all India Unani tibbi conference. Delhi. Aspin, J. R., Favus, M. J., and Coe, F. L. (1996). “Nephrolithiasis,” in Brenner and Rector’s the kidney. Editor B. M. Brenner. 5th ed. (Philadelphia: Saunders). 1893–1935.

Bashir, S., and Gilani, A. H. (2009). Antiurolithic effect of Bergenia ligulata rhizome: an explanation of the underlying mechanisms. Journal of Ethnopharmacology 122, 106–116. doi:10.1016/j.jep.2008.12.004

Chandhoke, P. S. (2002). When is Medical Prophylaxis Cost-effective for Recurrent Calcium Stones?. The Journal of Urology 168, 937–940. doi:10.1016/s0022-5347(05)00199-4

Dubey, N., Mehta, R. S., Saluja, A. K., and Jain, D. K. (2008). Quality assessment of Khusta-e-Gaodanti: a traditional Unani medicine. Asian J. Res. Chem. 1, 46–50.

Fan, J., Glass, M. A., and Chandhoke, P. S. (1999). Impact of ammonium chloride administration on rat ethylene glycol urolithiasis model. Scanning Microsc. 13, 299–306.

Gürocak, S., and Küpeli, B. (2006). Consumption of historical and current phytotherapeutic agents for urolithiasis: a critical review. Journal of Research 50, 456–455. doi:10.1016/j.juro.2006.03.034

Hardik, G., Maunuk, C., and Panakin, J. (2016). Diuretic and antiurolithiatic activities of an ethanolic extract of Acorus calamus L. rhizome in experimental animal models. J. Tradit Complement. Med. 6(4), 431–436. doi:10.1016/j.jtcme.2015.12.004

ETHICS STATEMENT

The animal study was reviewed and approved by Jamia Hamdard, Institutional Animal Ethics Committee (Registration Number 173/CPCSEA and Approval Number 691) following guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA).

AUTHOR CONTRIBUTIONS

WA: Experimental studies and manuscript preparation MK: Experimental studies and statistical analysis KA: Manuscript editing AA: Review and manuscript editing MA: Critical evaluation of manuscript KY: Literature review SW: Literature review SZ: Formulation preparation SA and MM: Conceived idea of research and data analysis.

ACKNOWLEDGMENTS

The authors would like to thank CCRUM for providing financial assistance and the Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India, for conceptualizing the project and providing the lab facility and technical assistance for conducting this study.
Hess, B., and Kok, D. J. (1996). Nucleation growth and aggregation of crystals. In: Kidney stones, medical and surgical management. Editors: Coo, F. L., Favus, M. J., Pak, C. Y., and Parks, J. H. Philadelphia, PA, USA: Lippincott-Raven. 3–32.

Ikshit, S., Washim, K., Rabea, P., Md. J., Iftekar, A., Mohd, H. R. A., et al. (2017). Antiurolithiasis activity of bioactivity guided fraction of bergenia ligulata against ethylene glycol induced renal calculi in rat. Biomed. Res. Int. 1969525. doi:10.1155/2017/1969525

Kato, J., Buram, A. A., Singh, S. S., Devi, S. B., Devi, T. I., and Singh, W. G. (2007). Lipid peroxidation and antioxidant vitamins in urolithiasis. Indian J. Clin. Biochem. 22, 128–130. doi:10.1007/bf02912895

Kaur, T., Bijarnia, R. K., Singla, S. K., and Tandon, C. (2009). Medicinal attributes of Solanum nanum (Accessed July 15, 2020). Int. J. Herb. Med. 1, 1–12.

Khan, M. A., Kumar, S., Gupta, A., and Ahmad, S. (2016). Screening of two new herbal formulations in rodent model of urolithiasis. Drug Dev. Ther. 7, 34–38. doi:10.4103/2394-6555.180160

Kumar, S., and Pandey, A. K. (2014). Medicinal attributes of Solanum xanthocarpum fruit consumed by several tribal communities as foodin in vitro antioxidant, anticancer and anti HIV perspective. BMC Complement. Altern. Med. 14, 112. doi:10.1186/1472-6882-14-112

Lin, W.-C., Lai, M.-T., Chen, H.-Y., Ho, C.-Y., Man, K.-M., Shen, J.-L., et al. (2012). Protective effect of Flos carthami extract against ethylene glycol-induced urolithiasis in rats. Urol. Res. 40, 655–661. doi:10.1007/s00240-012-0472-4

Mandavia, DR, Patel, MK, Patel, JC, Anovadiya, AP, Baxi, SN, and Tripathi, CR (2013). Anti-urolithiasis effect of ethanolic extract of Pedalium murex linn. fruits on ethylene glycol-induced renal calculi. Urol. J. 10, 946–952.

Moe, O. W. (2006). Kidney stones: pathophysiology and medical management. The Lancet 367, 333–344. doi:10.1016/s0140-6736(06)68071-9

Muthukumar, A., and Selvam, R. (1998). Role of glutathione on renal mitochondrial status in hyperoxaluria. Mol. Cel Biochem 185, 77–84. doi:10.1023/a:1006817319876

Nanu, R. R., Dipak, B., Havagaray, R. C., Sanjeev, R., and Sasmal, D. (2012). Anti-urolithiasis effects of Punica granatum in male rats. J. Ethnopharmacol. 140, 234–238. doi:10.1016/j.jep.2012.01.003

OECD (2020). OECD guidelines for the testing of chemical. Repeated dose 90 days oral toxicity study in rodents. Available at: https://www.oecd-ibibrary.org/docserver/9789264070707-n.pdf?expires=1616865109&id=id&accname=guest&checksum=2EECD6312717F23C7804C6E616492B

(Published July 15, 2020).

Pareta, SK, Patra, KC, Mazumder, PM, and Sasmal, D (2011). Aqueous extract of Boerhaavia diffusa root ameliorates ethylene glycol-induced hyperoxic oxidant stress and renal injury in rat kidney. Pharm. Biol. 49, 1224. doi:10.3109/13882029.2011.581671[Pub ahead of print]

Pattankar, S., Dohbada, S., Bhanisai, M., Khaladkar, S., and Modi, J. (2008). A prospective, randomized, controlled study to evaluate the efficacy and tolerability of Ayurvedic formulation “varuna and banana stem” in the management of urinary stones. J. Altern. Complement. Med. 14, 1287–1290. doi:10.1089/acm.2008.0189

Park, HK, Jeong, BC, Sung, MK, Park, MY, Choi, EY, Kim, BS, et al. (2007). Reduction of oxidative stress in cultured renal tubular cells and preventive effects on renal stone formation by the bioflavonoid quercetin. J. Urol. 179, 1620–6. doi:10.1016/j.juro.2007.11.039

Patel, M. J., and Med, J. R. Soc. (1989). Urolithiasis-historical, comparative and pathophysiological aspects: a review. Miner. Electrolyte Metab. 11, 20–31.

Potterat, O., and Hostetttman, K. (1995). “Plant source of natural drugs and compounds”. Encyclopedia of environmental biology. Editor W. A. Nierenberg (London: Academic Press), 13, 139–153.

Raven. 3

Saedi, I., Bozorgi, H. Zendehekel, A. and Mehrzad, J (2012). Therapeutic effects of aqueous extracts of Petroleumium sativum on ethylene glycol-induced kidney calculi in rats. Urol J 9, 361–6.

Saha, S., and Verma, RJ (2011). Bergenia ciliata extract prevents ethylene glycol induced histopathological changes in the kidney. Acta Pol. Pharm. 68, 711–5.

Sarithsh, R., Natarajan, K., and Nkikhad, M. M. (2010). Effect of Hygrospila spinosa tanders on ethylene glycol induced urolithiasis in rats. Asian J. Pharma. Clin. Res. 3, 61–63. doi:10.4103/0253-7613.100402

Shekar, K. M. G., and Patki, P. S. (2011). Evaluation of an Ayurvedic formulation (Cystone), in urolithiasis: a double blind, placebo-controlled study. Eur. J. Integr. Med. 3, 23–28. doi:10.1016/j.eujim.2011.02.003

Srinivas, S., Venkanna, B., Mohan, E. M., and Mohan, C. K. (2012). Urolithiasis: overview. Int. J. Pharma RBA. 1, 20–31.

Srinivasa, A. K. B., Kuruva, L., and Saran, G. S. (2013). Antiurolithiasis activity of Gokshuradichuran, an Ayurvedic formulation by in-vitro method. Adv. Pharm. Bull. 3, 477–479. doi:10.5681/apb.2013.080

Soudararajan, P., Kaheesh, R., Ramesh, T., and Hazeena, V. (2006). Effect of Aervulanta on calcium oxalate urolithiasis in rats. Indian J. Exp. Biol. 44, 981–986. doi:10.2514/1.17320

Sutherland, JW, Parks, JH, and Coe, FL (1985). Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab. 11, 267–9.

Tatke, P., Deshpande, S., and Nidhiya, I. S. R. (2012). Safety profile of a polyherbal formulation (gynocare capsules) in female rats by subchronic oral toxicity study. Toxicol. Int. 19, 106–110. doi:10.4103/0971-6580.97196

Verma, N. K., Patel, S. S., Saleem, T. S. M., Christina, A. J. M., and Chidambaranathan, N. (2009). Modulatory effect of NONI-Herbal formulation against ethylene glycol-induced nephrolithiasis in albino rats. J. Pharm. Sci. Res. 1, 83–89.

World Health Organization (2000). General guidelines for methodologies on research and evaluation of traditional medicine. Geneva: World Health Organization.

World Health Organization (1987). Principles for the safety assessment of food additives and contaminants in food. In IPCS environmental Health criteria 70. Geneva: World Health Organization.

World Health Organization (2002). World Health organization monographs on selected medicinal plants. Geneva: World Health Organization. 159. doi:10.1111/j.2042-7166.2000.tb02454.x

Zaidi, S. M. A., and Ahmad, W. (2016). Randomized single-blind clinical evaluation of Safoof-e-Pacific Phor in urolithiasis patients. Drug Dev. Ther. 7 (2), 92–95. doi:10.4103/2394-6555.191151

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Ahmad, Khan, Asif, Ahmad, Dawud Ali, Ansari, Kamal, Wahab, Zaidi, Majeed and Ahmad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.